Cucurbitacin is a highly selective inhibitor of STAT3 signaling (32, 33) reported to target STAT3 in CLL (33), with no significant effect on other pro-survival pathways within malignant cells, such as Ras–raf–MEK–ERK and PI3k/Akt. The gene discussed is MAP2K7; the disease is B-cell chronic lymphocytic leukemia.